Cells (Jun 2022)
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test
- Damien Vasseur,
- Hela Sassi,
- Arnaud Bayle,
- Marco Tagliamento,
- Benjamin Besse,
- Christophe Marzac,
- Ahmadreza Arbab,
- Nathalie Auger,
- Sophie Cotteret,
- Mihaela Aldea,
- Félix Blanc-Durand,
- Arthur Géraud,
- Anas Gazzah,
- Yohann Loriot,
- Antoine Hollebecque,
- Patricia Martín-Romano,
- Maud Ngo-Camus,
- Claudio Nicotra,
- Santiago Ponce,
- Madona Sakkal,
- Olivier Caron,
- Cristina Smolenschi,
- Jean-Baptiste Micol,
- Antoine Italiano,
- Etienne Rouleau,
- Ludovic Lacroix
Affiliations
- Damien Vasseur
- Medical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, France
- Hela Sassi
- Medical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, France
- Arnaud Bayle
- Drug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, France
- Marco Tagliamento
- Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France
- Benjamin Besse
- Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France
- Christophe Marzac
- Medical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, France
- Ahmadreza Arbab
- Medical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, France
- Nathalie Auger
- Medical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, France
- Sophie Cotteret
- Medical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, France
- Mihaela Aldea
- Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France
- Félix Blanc-Durand
- Gynecological Cancer Unit, Department of Medicine, Gustave Roussy, F-94805 Villejuif, France
- Arthur Géraud
- Drug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, France
- Anas Gazzah
- Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France
- Yohann Loriot
- Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France
- Antoine Hollebecque
- Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France
- Patricia Martín-Romano
- Drug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, France
- Maud Ngo-Camus
- Drug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, France
- Claudio Nicotra
- Drug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, France
- Santiago Ponce
- Drug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, France
- Madona Sakkal
- Dermatology Unit, Oncology Department, Gustave Roussy, F-94805 Villejuif, France
- Olivier Caron
- Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France
- Cristina Smolenschi
- Dermatology Unit, Oncology Department, Gustave Roussy, F-94805 Villejuif, France
- Jean-Baptiste Micol
- Department of Hematology, Gustave Roussy, F-94805 Villejuif, France
- Antoine Italiano
- Drug Development Department (DITEP), Gustave Roussy, F-94805 Villejuif, France
- Etienne Rouleau
- Medical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, France
- Ludovic Lacroix
- Medical Biology and Pathology Department, Gustave Roussy, F-94805 Villejuif, France
- DOI
- https://doi.org/10.3390/cells11121901
- Journal volume & issue
-
Vol. 11,
no. 12
p. 1901
Abstract
FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short turnaround time. It gives the opportunity to study the heterogeneity of the tumor, to elucidate complex resistance mechanisms and to adapt treatment strategies. However, lowering the limit of detection and increasing the panels’ size raise new questions in terms of detection of incidental germline alterations, occult malignancies and clonal hematopoiesis of indeterminate potential mutations. In this review, after a technological discussion and description of the common problematics encountered, we establish recommendations in properly using these FDA-approved tests in a molecular-tumor-board context.
Keywords